Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Current Quarter	$-0.54	Next Quarter	$-0.48
Current Year	$-2.1	Next Year	$-2.13
QoQ Growth	+11.1%	YoY Growth	-1.4%
3Y EPS CAGR	N/A	Target Price	$20.00
Consensus	Buy	Upside	+54.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATXS	$12.92	-0.08%	1.05M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATXS	$12.92	-0.1%	1.05M
3
4
5
6

ATXS

ATXS

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Astria Therapeutics Inc. Data in Excel

Get Astria Therapeutics Inc. Data in Excel